181 related articles for article (PubMed ID: 32508056)
1. A four-factor immune risk score signature predicts the clinical outcome of patients with spinal chordoma.
Zou MX; Pan Y; Huang W; Zhang TL; Escobar D; Wang XB; Jiang Y; She XL; Lv GH; Li J
Clin Transl Med; 2020 Jan; 10(1):224-237. PubMed ID: 32508056
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of a 6-miRNA Prognostic Signature in Spinal Chordoma.
Huang W; Yan YG; Wang WJ; Ouyang ZH; Li XL; Zhang TL; Wang XB; Wang B; Lv GH; Li J; Zou MX
Front Oncol; 2020; 10():556902. PubMed ID: 33194623
[TBL] [Abstract][Full Text] [Related]
3. Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor.
Zou MX; Lv GH; Wang XB; Huang W; Li J; Jiang Y; She XL
Neurosurgery; 2019 Jun; 84(6):E318-E333. PubMed ID: 30032257
[TBL] [Abstract][Full Text] [Related]
4. Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients.
Xia C; Huang W; Chen YL; Fu HB; Tang M; Zhang TL; Li J; Lv GH; Yan YG; Ouyang ZH; Yao N; Wang C; Zou MX
Front Immunol; 2021; 12():797407. PubMed ID: 35145510
[TBL] [Abstract][Full Text] [Related]
5. The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma.
Zou MX; Zheng BW; Liu FS; Wang XB; Hu JR; Huang W; Dai ZH; Zhang QS; Liu FB; Zhong H; Jiang Y; She XL; Li XB; Lv GH; Li J
Neurosurgery; 2019 Dec; 85(6):E1095-E1110. PubMed ID: 31501892
[TBL] [Abstract][Full Text] [Related]
6. An individualized immune prognostic signature in lung adenocarcinoma.
Sun L; Jiang G; Gonzalez-Rivas D; Zhang P
Cancer Cell Int; 2020; 20():156. PubMed ID: 32410884
[TBL] [Abstract][Full Text] [Related]
7. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of an Immune-Based Prognostic Risk Score for Patients With Resected Non-Small Cell Lung Cancer.
He L; Huang Y; Chen X; Huang X; Wang H; Zhang Y; Liang C; Li Z; Yan L; Liu Z
Front Immunol; 2022; 13():835630. PubMed ID: 35401554
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analyses of a tumor-infiltrating lymphocytes-related gene signature regarding the prognosis and immunologic features for immunotherapy in bladder cancer on the basis of WGCNA.
He Z; Gu J; Luan T; Li H; Li C; Chen Z; Luo E; Wang J; Huang Y; Ding M
Front Immunol; 2022; 13():973974. PubMed ID: 36211333
[TBL] [Abstract][Full Text] [Related]
10. Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.
Zou MX; Peng AB; Lv GH; Wang XB; Li J; She XL; Jiang Y
Am J Transl Res; 2016; 8(7):3274-87. PubMed ID: 27508049
[TBL] [Abstract][Full Text] [Related]
11. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
12. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
13. Association of the Collagen Signature in the Tumor Microenvironment With Recurrence and Survival of Patients With T4N0M0 Colon Cancer.
Chen W; Dong S; Liu X; Wang G; Xu S; Lei S; Zhuo S; Yan J
Dis Colon Rectum; 2021 May; 64(5):563-575. PubMed ID: 33538520
[TBL] [Abstract][Full Text] [Related]
14. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
[TBL] [Abstract][Full Text] [Related]
15. A model based on tumor-infiltrating immune cells for predicting the relapse rates of patients with testicular germ cell tumors.
Wang Y; Ji C; Liu J; Wang Y; Song N; Cao P
Int Immunopharmacol; 2020 Sep; 86():106710. PubMed ID: 32652500
[TBL] [Abstract][Full Text] [Related]
16. Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour.
Wei ZW; Wu J; Huang WB; Li J; Lu XF; Yuan YJ; Xiong WJ; Zhang XH; Wang W; He YL; Zhang CH
EBioMedicine; 2020 Jul; 57():102850. PubMed ID: 32574962
[TBL] [Abstract][Full Text] [Related]
17. Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma.
Tian MX; Liu WR; Wang H; Zhou YF; Jin L; Jiang XF; Tao CY; Tang Z; Zhou PY; Fang Y; Qu WF; Ding ZB; Peng YF; Dai Z; Qiu SJ; Zhou J; Lau WY; Fan J; Shi YH
BMC Med; 2019 Jun; 17(1):106. PubMed ID: 31164128
[TBL] [Abstract][Full Text] [Related]
18. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer.
Brown JR; Wimberly H; Lannin DR; Nixon C; Rimm DL; Bossuyt V
Clin Cancer Res; 2014 Dec; 20(23):5995-6005. PubMed ID: 25255793
[TBL] [Abstract][Full Text] [Related]
19. Identification of an IDO1-based immune classifier for survival prediction of upper tract urothelial carcinoma.
Zhong W; Yang M; Cheng S; Hou W; Wang B; Chen J; Yu H; Ouyang Y; Wang X; Ou Z; Xu P; Li X; Zhou L; Huang J; Wang C; Lin T
Cancer Sci; 2022 Mar; 113(3):852-863. PubMed ID: 34962030
[TBL] [Abstract][Full Text] [Related]
20. Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma.
Deng PZ; Zhao BG; Huang XH; Xu TF; Chen ZJ; Wei QF; Liu XY; Guo YQ; Yuan SG; Liao WJ
World J Gastroenterol; 2022 Aug; 28(31):4376-4389. PubMed ID: 36159012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
